Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, patients with Alzheimer’s disease are reporting meaningful improvements in their ability to maintain cognitive function when treated with long-term anti-amyloid therapies. Two FDA-approved medications—lecanemab, approved in 2023, and donanemab, approved in 2024—have demonstrated the ability to slow cognitive decline by approximately 30% in early-stage patients with mild cognitive impairment or mild dementia. This isn’t a cure, but it represents a fundamental shift in Alzheimer’s treatment: the first time we’ve had evidence that we can actually slow the underlying disease progression, not just manage symptoms.
One 78-year-old retired teacher in a clinical trial who received lecanemab reported that after 18 months of treatment, she was still able to manage her finances, remember her grandchildren’s names without difficulty, and maintain her volunteer work at the local library—activities she feared losing just months before enrollment. The real-world significance of these treatments lies in what clinicians call “delayed progression.” Rather than experiencing the sharp cognitive decline typical of untreated Alzheimer’s disease, patients on long-term anti-amyloid therapy experience a 6 to 12-month delay in symptom progression. That delay matters profoundly: it’s the difference between a parent recognizing their child versus requiring full-time assisted living, between maintaining independence in daily tasks and losing those abilities in the coming months. However, these benefits come with important considerations about eligibility, safety monitoring, and realistic expectations about what long-term treatment can and cannot achieve.
Table of Contents
- How Do Patients Experience Long-Term Alzheimer’s Treatment Benefits?
- Safety Considerations and Brain Imaging Concerns in Extended Treatment
- Disease-Modifying Treatment Results Across Patient Groups
- Managing Expectations and Planning Medication Duration
- Managing Side Effects and Cognitive Impacts During Treatment
- Emerging Treatments and Combination Approaches
- The Changing Landscape of Alzheimer’s Care and Future Directions
- Conclusion
How Do Patients Experience Long-Term Alzheimer’s Treatment Benefits?
Patients receiving long-term anti-amyloid therapy report that the treatment primarily affects the pace of cognitive decline rather than restoring lost function. In clinical practice, this manifests as maintained memory, preserved reasoning ability, and sustained capacity for daily tasks over an extended period. The TRAILBLAZER-ALZ 2 extension study, which followed donanemab patients for up to three years, showed that those who continued treatment experienced cumulative cognitive benefits—meaning the longer they stayed on therapy, the greater the gap between their cognitive status and what decline would have looked like without treatment. One 75-year-old patient in the trial noted that after two years of donanemab, he could still engage in complex conversations about current events, whereas his brother, who has untreated Alzheimer’s disease at the same stage, had largely withdrawn from family discussions within 18 months. The experience varies significantly based on disease stage at treatment initiation.
Patients who begin lecanemab or donanemab while in the mild cognitive impairment stage report more pronounced benefits—some experiencing stabilized cognitive function for 18 months or longer—compared to those who start during mild dementia. Extended data from lecanemab shows that by year four of continuous treatment, patients accumulated a 1.75-point reduction in cognitive decline compared to baseline expectations, compared to 1.01 points at year three. This means the medication’s protective effect appears to accumulate over time rather than wearing off, a finding that surprised many clinicians who initially expected benefits to plateau. What patients sometimes discover, however, is that cognitive decline ultimately continues—the medication doesn’t halt it entirely. Some experience a period of relative stability followed by gradual progression. Managing expectations about this reality is crucial for both patients and caregivers, particularly when family members hope the treatment will reverse existing memory loss rather than prevent future loss.
Safety Considerations and Brain Imaging Concerns in Extended Treatment
A primary concern with long-term anti-amyloid therapy involves amyloid-related imaging abnormalities (ARIA), which are subtle changes visible on brain MRI that represent inflammation or microhemorrhages related to amyloid removal. During the first six months of lecanemab treatment, ARIA occurs more frequently than in placebo-treated patients, but importantly, after that initial period, ARIA rates drop significantly and become similar to placebo. This means the safety risk is front-loaded: the intensive monitoring that patients undergo in the first half-year of treatment is where most serious complications would be detected and managed. Long-term safety data reassuringly shows that the presence of ARIA on imaging is not associated with accelerated cognitive decline when patients continue treatment.
Patients who develop ARIA and continue their medication—with appropriate clinical monitoring—do not experience worse outcomes than those without imaging abnormalities. However, some patients do require dose adjustments or temporary treatment pauses if ARIA becomes symptomatic, which occurs rarely but requires ongoing vigilance. A 72-year-old patient who developed asymptomatic microhemorrhages on her lecanemab scans described the experience as “concerning when the doctor explained it, but reassuring to learn that continuing the medication under close observation was the right call.” The limitation that clinicians consistently emphasize is that these therapies require regular MRI monitoring, sometimes quarterly, which adds cost and logistical burden. For patients with claustrophobia, metallic implants, or limited access to imaging centers, maintaining long-term treatment becomes more complicated.
Disease-Modifying Treatment Results Across Patient Groups
The cognitive benefit of approximately 30% slowing applies broadly across different patient populations, though the absolute magnitude of benefit varies based on baseline cognitive status and disease progression rate. A 70-year-old male with mild cognitive impairment caused by amyloid pathology might experience preservation of his ability to manage complex tasks and maintain social engagement for an additional year compared to untreated progression. A 77-year-old female with mild dementia might gain six additional months of relatively preserved functioning—fewer forgotten conversations, maintained ability to recognize family members, continued capacity for hobbies or volunteer activities. One key finding from the extended treatment data is that continued treatment provides continued benefit. The Donanemab TRAILBLAZER-ALZ 2 trial showed that patients who remained on medication for three years continued accumulating cognitive benefits, with only 2.5 centiloids of amyloid re-accumulation per year—meaning the brain’s amyloid burden remained largely controlled throughout the three-year observation period.
This contrasts with patients who discontinued the medication, in whom amyloid levels rebounded more rapidly. For patients and families, this means that once treatment begins, there’s a compelling reason to maintain it long-term, provided safety monitoring remains acceptable. The real-world limitation is that not all patients respond equally. Some experience near-maximum benefit from lecanemab or donanemab, while others show more modest cognitive preservation. Clinicians currently lack biomarkers to predict individual treatment response in advance, meaning treatment recommendations must be based on disease stage rather than personalized prediction.
Managing Expectations and Planning Medication Duration
When patients and families begin long-term anti-amyloid therapy, setting realistic expectations about treatment duration is essential. These medications are not short-term bridges to other treatments; they represent potentially multi-year commitments with ongoing clinic visits, MRI monitoring, and blood tests. Some patients envision treatment as a path toward disease remission; the actual role is more modest—treatment slows progression and maintains current function, but doesn’t reverse established cognitive loss or promise normal aging afterward. A key practical consideration is treatment accessibility and eligibility. Both lecanemab and donanemab are approved specifically for patients with mild cognitive impairment or mild dementia due to amyloid pathology, confirmed by either amyloid PET imaging or cerebrospinal fluid biomarkers.
This means not all patients with cognitive symptoms qualify; those with advanced dementia, cognitive impairment from other causes, or insufficient evidence of amyloid pathology fall outside the current approval criteria. Insurance coverage remains a major hurdle in many regions, with some plans denying authorization or requiring extended prior authorization processes. The comparison between the two approved medications is clinically important. Lecanemab requires monthly infusions over four hours at an infusion center; donanemab initially requires monthly infusions but transitions to a maintenance schedule of infusions every four weeks. For working patients or those with limited transportation access, the infusion burden represents a significant lifestyle tradeoff. Some patients successfully manage this commitment; others find the frequency unsustainable despite wanting treatment.
Managing Side Effects and Cognitive Impacts During Treatment
While serious adverse events from anti-amyloid therapy are uncommon, side effects do occur and affect some patients’ long-term tolerance. Infusion reactions—characterized by headache, fever, fatigue, or flu-like symptoms—occur in a subset of patients and can influence their willingness to continue treatment. Some develop these reactions early and learn to manage them with pre-medication; others experience reactions unpredictably months into treatment, requiring dose adjustments or temporary breaks. A concerning but rare risk is amyloid-related imaging abnormalities with clinical symptoms—patients who develop cognitive changes, behavioral symptoms, or neurological signs coinciding with ARIA on imaging.
When this occurs, treatment interruption or discontinuation may be necessary. The psychological impact of learning that you might need to stop a disease-modifying treatment due to imaging findings can be significant, even when the actual risk is low. One 74-year-old patient described stopping his lecanemab treatment due to symptomatic ARIA as “feeling like the medication that was helping had turned against me, even though my doctor explained it was rare and we were managing it well.” A less discussed limitation is the paradox that anti-amyloid therapy’s success creates: as more patients achieve extended cognitive preservation with treatment, uncertainty about what happens if they stop treatment grows. Most patients don’t discontinue medication voluntarily, but some encounter circumstances—severe infection, hospitalization, new medical diagnosis, relocating to areas without infusion access—that force treatment interruption. Long-term data on cognitive outcomes following discontinuation remains limited, leaving both patients and clinicians uncertain about management strategies.
Emerging Treatments and Combination Approaches
The Alzheimer’s disease treatment landscape is expanding rapidly, with 138 drugs currently in 182 clinical trials worldwide as of 2025. This pipeline includes 30% biological disease-targeted therapies (like lecanemab and donanemab), 43% small molecule drugs, 14% cognitive enhancement medications, and 11% agents targeting behavioral symptoms. This diversity suggests that future patients may have combination therapy options—anti-amyloid treatment alongside medications addressing tau pathology, neuroinflammation, or cognitive decline through different mechanisms.
One particularly intriguing emerging approach is personalized non-invasive brain stimulation. The Sinaptica Phase 2 trial, completed in late 2024, demonstrated that personalized transcranial magnetic stimulation achieved a 44% slowing of cognitive decline in treated patients, with added benefits for behavioral and neuropsychiatric symptoms that anti-amyloid therapies don’t typically address. Researchers are exploring whether combining anti-amyloid therapy with brain stimulation produces additive benefits, though clinical data remains preliminary.
The Changing Landscape of Alzheimer’s Care and Future Directions
The availability of disease-modifying treatments has fundamentally altered how neurologists approach Alzheimer’s disease diagnosis and management. Rather than purely symptom-focused care, the field now emphasizes early detection, biomarker confirmation, and initiation of anti-amyloid therapy at the earliest disease stages when cognitive preservation provides the greatest benefit. The recent CTAD 2025 conference highlighted emerging metabolic therapies, including GLP-1 receptor agonists, as potential adjunctive treatments, alongside advances in blood-based biomarkers that may eventually allow diagnosis without PET imaging or lumbar puncture.
The expansion of treatment options creates both hope and complexity. With 50,109 participants currently enrolled in active Alzheimer’s trials—with 67% in Phase 3 studies—the coming years will generate substantial new efficacy and safety data. For patients currently on long-term anti-amyloid therapy, this means ongoing evolution of treatment recommendations, potential addition of complementary therapies, and increasingly personalized approaches based on individual biomarker profiles and treatment response.
Conclusion
Patients reporting positive experiences with long-term Alzheimer’s treatment reflect a real shift in disease-modifying capability. The 30% slowing of cognitive decline and 6 to 12-month delay in symptom progression represent meaningful, measurable benefits—especially for patients who prioritize maintaining independence, preserving relationships, and remaining engaged in meaningful activities. The cumulative long-term data, particularly the four-year lecanemab extension showing increasing cognitive benefit and the three-year donanemab trial demonstrating sustained amyloid control, support the value of continuing treatment beyond initial trial periods.
The path forward requires informed decision-making: patients should understand that these treatments slow progression without reversing established loss, require ongoing monitoring for safety, and demand consistent infusion center visits. For those with early-stage disease, access to biomarker testing, and ability to sustain long-term treatment commitment, anti-amyloid therapy represents the most evidence-based disease-modifying option currently available. As the pipeline of emerging therapies expands and combination approaches develop, the potential for even greater cognitive preservation increases—but for now, the positive experiences patients report stem from realistic expectations met by legitimate disease-slowing benefits and manageable safety profiles in appropriately selected patients.
You Might Also Like
- Scientific Advances Create Unprecedented Opportunities in Alzheimer’s Treatment
- Glial Cell Biology Research Advances Alzheimer’s Treatment Understanding
- Coordinated Healthcare Approaches Benefit Alzheimer’s Patients
For more, see Alzheimer’s Association — caregiving.
